🇺🇸 FDA
Patent

US 9181273

Morpholine-spirocyclic piperidine amides as modulators of ion channels

granted A61PA61P1/00A61P1/02

Quick answer

US patent 9181273 (Morpholine-spirocyclic piperidine amides as modulators of ion channels) held by Vertex Pharmaceuticals Incorporated expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61P, A61P1/00, A61P1/02, A61P1/04, A61P1/16